Steroid Receptor Status, Proliferation and Metallothionein Expression in Primary Invasive Ductal Breast Cancers

Overview

Journal Pathol Oncol Res

Specialty Oncology

Date 2004 Dec 28

PMID 15619641

Citations 2

Authors

Pawel Surowiak

Piotr Paluchowski

Teresa Wysocka

Andrzej Wojnar

Maciej Zabel

Affiliations

Soon will be listed here.

Abstract

The most important immunocytochemical prognostic and predictive factors in cases of breast cancer include estrogen receptor alpha (ER) and progesterone receptor (PgR). The present study aimed at examining the relationship between the manifestation intensity of proliferation markers (Ki-67 and nucleolar organizer regions--AgNORs) on one hand, and expression of ER and PgR on the other in a uniform group of invasive ductal breast cancers of G2 grade. Moreover, the study aimed at examining the relationship between the above mentioned markers and expression of metallothionein (MT). The studies were performed on samples of invasive ductal breast cancers of G2 grade, originating from 60 females. In paraffin sections originating from the studied cases immunocytochemical reactions were performed using monoclonal antibodies to ER, PgR, Ki-67 and MT, and silver staining was conducted to localize AgNORs. The obtained results were subjected to statistical analysis using Statistica software. Results indicate that manifestation of AgNORs does not correlate with any of the studied antigens (ER, PgR, Ki-67, MT) (p>0.05). Moreover, no relationship could be demonstrated between the intensity of MT expression and proliferation markers or steroid receptor status (p>0.05). A negative correlation was shown between the expression of ER and Ki-67 (p=0.0009). The most intense proliferative activity was demonstrated in cases of breast cancer showing PgR expression but no ER expression (p=0.015), while the lowest proliferative activity was detected in breast cancers with expression of both ER and PgR (p<0.05).

Citing Articles

Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrence.

Demicheli R, Biganzoli E, Ardoino I, Boracchi P, Coradini D, Greco M Cancer Sci. 2010; 101(3):826-30.

PMID: 20132222 PMC: 11159972. DOI: 10.1111/j.1349-7006.2009.01472.x.

Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions.

El Sharkawy S, Abbas N, Badawi M, El Shaer M J Clin Pathol. 2006; 59(11):1171-4.

PMID: 16574721 PMC: 1860510. DOI: 10.1136/jcp.2005.033746.

References

Biesterfeld S, Farokhzad F, Kluppel D, Schneider S, Hufnagl P . Improvement of breast cancer prognostication using cell kinetic-based silver-stainable nucleolar organizer region quantification of the MIB-1 positive tumor cell compartment. Virchows Arch. 2001; 438(5):478-84. DOI: 10.1007/s004280000351. View

Schwint A, Folco A, Morales A, Cabrini R, Itoiz M . AgNOR mark epithelial foci in malignant transformation in hamster cheek pouch carcinogenesis. J Oral Pathol Med. 1996; 25(1):20-4. DOI: 10.1111/j.1600-0714.1996.tb01218.x. View

Keshgegian A, Cnaan A . Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome. Arch Pathol Lab Med. 1996; 120(10):970-3. View

Hishikawa Y, Koji T, Dhar D, Kinugasa S, Yamaguchi M, Nagasue N . Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. Br J Cancer. 1999; 81(4):712-20. PMC: 2362883. DOI: 10.1038/sj.bjc.6690753. View

Zaslawski R, Surowiak P, Dziegiel P, Pretnik L, Zabel M . Analysis of the expression of estrogen and progesteron receptors, and of PCNA and Ki67 proliferation antigens, in uterine myomata cells in relation to the phase of the menstrual cycle. Med Sci Monit. 2001; 7(5):908-13. View

Clahsen P, van de Velde C, Duval C, Pallud C, Mandard A, van den Broek L . The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol. 1999; 25(4):356-63. DOI: 10.1053/ejso.1999.0657. View

Harris H, Henderson R, Bhat R, Komm B . Regulation of metallothionein II messenger ribonucleic acid measures exogenous estrogen receptor-beta activity in SAOS-2 and LNCaPLN3 cells. Endocrinology. 2001; 142(2):645-52. DOI: 10.1210/endo.142.2.7952. View

Jin R, Tan P, Dheen S, Duan W, Bay B . Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis. 2002; 23(1):81-6. DOI: 10.1093/carcin/23.1.81. View

Surowiak P, Dziegiel P, Zabel M, Matkowski R, Kornafel J . Analysis of estrogen receptor (ER) and estrogen-dependent pS2 protein expression in cells of mammary ductal carcinoma. Folia Histochem Cytobiol. 2001; 39(2):141-2. View

10.

Friedline J, Garrett S, Somji S, Todd J, Sens D . Differential expression of the MT-1E gene in estrogen-receptor-positive and -negative human breast cancer cell lines. Am J Pathol. 1998; 152(1):23-7. PMC: 1858136. View

11.

JENSEN E, Cheng G, Palmieri C, Saji S, Makela S, Van Noorden S . Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A. 2001; 98(26):15197-202. PMC: 65006. DOI: 10.1073/pnas.211556298. View

12.

KAGI J . Overview of metallothionein. Methods Enzymol. 1991; 205:613-26. DOI: 10.1016/0076-6879(91)05145-l. View

13.

Schmidt C, Hamer D . Cell specificity and an effect of ras on human metallothionein gene expression. Proc Natl Acad Sci U S A. 1986; 83(10):3346-50. PMC: 323510. DOI: 10.1073/pnas.83.10.3346. View

14.

Ioachim E, Assimakopoulos D, Peschos D, Zissi A, Skevas A, Agnantis N . Immunohistochemical expression of metallothionein in benign premalignant and malignant epithelium of the larynx: correlation with p53 and proliferative cell nuclear antigen. Pathol Res Pract. 2000; 195(12):809-14. DOI: 10.1016/S0344-0338(99)80102-2. View

15.

Zhang R, Zhang H, Wei H, Luo X . Expression of metallothionein in invasive ductal breast cancer in relation to prognosis. J Environ Pathol Toxicol Oncol. 2000; 19(1-2):95-7. View

16.

Fitzgibbons P, Page D, Weaver D, Thor A, Allred D, Clark G . Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000; 124(7):966-78. DOI: 10.5858/2000-124-0966-PFIBC. View

17.

Ploton D, Menager M, Jeannesson P, Himber G, Pigeon F, Adnet J . Improvement in the staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level. Histochem J. 1986; 18(1):5-14. DOI: 10.1007/BF01676192. View

18.

Detre S, King N, Salter J, MacLennan K, McKinna J, Dowsett M . Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer. J Clin Pathol. 1994; 47(3):240-4. PMC: 501903. DOI: 10.1136/jcp.47.3.240. View

19.

Jin R, Bay B, Chow V, Tan P . Metallothionein 1F mRNA expression correlates with histological grade in breast carcinoma. Breast Cancer Res Treat. 2001; 66(3):265-72. DOI: 10.1023/a:1010658907462. View

20.

Remmele W, Stegner H . [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987; 8(3):138-40. View